To evaluate the effect on cerebral gray matter atrophy in patients with relapsing-remitting multiple sclerosis starting Glatiramer acetate

Trial Profile

To evaluate the effect on cerebral gray matter atrophy in patients with relapsing-remitting multiple sclerosis starting Glatiramer acetate

Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2017

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 06 May 2017 New trial record
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top